|
Tristel PLC on Monday backed its ability to deliver revenue growth and strong profitability, as it posted a near 20% gain in full-year profit. The Newmarket, England-based maker of infection prevention products reported pretax profit of £8.4 million for the financial year that ended June 30, up 19% from £7.1 million a year earlier. Driving the advance was an 11% top-line gain, as revenue rose to £46.5 million from £41.9 million. Tristel credited this improvement to a combination of higher sales volumes and price increases. The company reported an 11% gain in medical device sales to £40.4 million from £36.4 million, with this reinforcing its ‘ability to continually grow on [its] market leadership position.’ Tristel did face increased administrative expenses during the period, up 9.3% to £28.7 million from £26.2 million, limiting bottom line gains. Shares in the company were down 0.3% to 356.80 pence midday Monday in London. Tristel declared a final dividend of 8.52p, up from 8.28p a year before, making for a total annual dividend of 14.20p per share, up 5.0% from 13.52p. Commenting on trading since the start of the new financial year in July, Tristel said demand in the US ‘remains significant’, as it noted a high volume of leads with engagement across around 200 health systems. Anna Wasyl started as chief financial officer last month, replacing Liz Dixon, who departed in June. ‘Tristel has delivered another strong year...This performance reflects the strength of our core business, robust cash generation and continued disciplined execution, enabling us to increase the dividend while maintaining a debt-free balance sheet,’ said Chief Executive Matt Sassone. ‘With Anna joining the board, new product launches...and a solid cash position, the board remains confident in our ability to deliver sustained revenue growth, strong profitability, and attractive shareholder returns.’ Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
